{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267758","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.096053+00:00","generated_at":"2026-06-09T02:54:40.863252+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Spero Therapeutics appoints Esther Rajavelu as CFO and CBO effective Nov 6","bullets":["Esther Rajavelu appointed CFO and Chief Business Officer; assumes principal financial officer role after Q3 10-Q filing.","Annual base salary of $475,000; sign-on bonus of $50,000; target annual cash bonus of 40% of base salary.","Grant of 300,000 RSUs under inducement plan, vesting in equal annual installments over four years starting Nov 6, 2024.","Interim CFO Stephen DiPalma continues until Q3 10-Q filed; may consult post-transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267758","json":"https://secwatch.observer/filing/0001193125-23-267758.json","markdown":"https://secwatch.observer/filing/0001193125-23-267758.md","text":"https://secwatch.observer/filing/0001193125-23-267758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/0001193125-23-267758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/d506257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:54:40.863252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aee6507d42","claim":"Esther Rajavelu was appointed as Chief Financial Officer and Chief Business Officer at Spero Therapeutics, Inc..","evidence_excerpt":"On October 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Chief Business Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/0001193125-23-267758-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}